- Home
- HOPE vs SVRA Comparison
HOPE vs SVRA Comparison
Compare HOPE & SVRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HOPE | SVRA |
|---|---|---|
| Founded | 1986 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.1B |
| IPO Year | 2000 | 2009 |
Fundamental Metrics
Financial Performance| Metric | HOPE | SVRA |
|---|---|---|
| Price | $10.77 | $5.50 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 9 |
| Target Price | ★ $13.75 | $7.33 |
| AVG Volume (30 Days) | 734.9K | ★ 1.3M |
| Earning Date | 04-28-2026 | 01-01-0001 |
| Dividend Yield | ★ 5.14% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.49 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $38.10 | N/A |
| Revenue Next Year | $10.98 | N/A |
| P/E Ratio | $22.26 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $8.83 | $1.89 |
| 52 Week High | $12.79 | $7.01 |
Technical Indicators
Market Signals| Indicator | HOPE | SVRA |
|---|---|---|
| Relative Strength Index (RSI) | 30.69 | 47.05 |
| Support Level | $10.72 | $5.47 |
| Resistance Level | $10.99 | $6.10 |
| Average True Range (ATR) | 0.35 | 0.28 |
| MACD | -0.11 | -0.02 |
| Stochastic Oscillator | 7.10 | 32.62 |
Price Performance
Historical ComparisonAbout HOPE Hope Bancorp Inc.
Hope Bancorp Inc is a bank holding company engaged in providing financial services. It offers core business banking products for small and medium-sized businesses and individuals. Services offered by the bank include online banking, mobile banking, mortgage loans, credit cards, investment and wealth management services, and other banking services.
About SVRA Savara Inc.
Savara Inc is a biopharmaceutical company. It is focused on rare respiratory diseases. The company's program, molgramostim nebulizer solution (molgramostim), is an inhaled granulocyte-macrophage colony-stimulating factor in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). It has one segment specialty pharmaceuticals within the respiratory system.